Suven Life Sciences has secured grant of four product patents, one from Europe, one from New Zealand, one from Australia and one from Korea corresponding to the New Chemical Entities (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid through 2025.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD) , Huntingon’s disease, Parkinson and Schizophrenia.
With these patents, Suven has a total of eight granted patents from Europe, ten granted patents from New Zealand, nine granted patents from korea for the NCEs. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.
